New targets for drug development in asthma

[1]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[2]  S. Holgate,et al.  Pathogenesis of Asthma , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[3]  S. Durham,et al.  Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. , 2008, The Journal of allergy and clinical immunology.

[4]  D. Postma,et al.  RETRACTED ARTICLE: Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? , 2008, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  I. Adcock,et al.  Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma , 2008, Thorax.

[6]  S. Dahlén,et al.  The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level , 2008, European Respiratory Journal.

[7]  L. Boulet,et al.  Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. , 2008, American journal of respiratory and critical care medicine.

[8]  P. Chakravarty,et al.  Curcumin restores corticosteroid function in monocytes exposed to oxidants by maintaining HDAC2. , 2008, American journal of respiratory cell and molecular biology.

[9]  J. O’Shea,et al.  Cytokine signaling modules in inflammatory responses. , 2008, Immunity.

[10]  A. Nel,et al.  T-cell effector pathways in allergic diseases: transcriptional mechanisms and therapeutic targets. , 2008, The Journal of allergy and clinical immunology.

[11]  Tak H. Lee,et al.  Therapeutic approaches for control of transcription factors in allergic disease. , 2008, The Journal of allergy and clinical immunology.

[12]  S. Keslacy,et al.  Cytokines induce an early steroid resistance in airway smooth muscle cells: novel role of interferon regulatory factor-1. , 2008, American journal of respiratory cell and molecular biology.

[13]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[14]  H. Hammad,et al.  Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma , 2008, Nature Reviews Immunology.

[15]  Christopher M. Tan,et al.  Adenovirus IL-13-induced airway disease in mice: a corticosteroid-resistant model of severe asthma. , 2008, American journal of respiratory cell and molecular biology.

[16]  M. Ichinose,et al.  Nitrative stress in refractory asthma. , 2008, The Journal of allergy and clinical immunology.

[17]  S. Holgate,et al.  The role of a soluble TNFα receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial , 2008, Thorax.

[18]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[19]  E. Vajda,et al.  Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein–protein interaction profile , 2007, Proceedings of the National Academy of Sciences.

[20]  B. Lambrecht,et al.  GATA3-Driven Th2 Responses Inhibit TGF-β1–Induced FOXP3 Expression and the Formation of Regulatory T Cells , 2007, PLoS biology.

[21]  B. Levy,et al.  Lipoxin A4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonism , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  A. Woodcock,et al.  Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. , 2007, American journal of respiratory and critical care medicine.

[23]  K. Kuntz,et al.  Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. , 2007, The Journal of allergy and clinical immunology.

[24]  W. Henderson,et al.  Mechanisms of disease: Leukotrienes , 2007 .

[25]  P. Barnes,et al.  The Role of IκB Kinase 2, but Not Activation of NF-κB, in the Release of CXCR3 Ligands from IFN-γ-Stimulated Human Bronchial Epithelial Cells , 2007, The Journal of Immunology.

[26]  Peter J Sterk,et al.  An electronic nose in the discrimination of patients with asthma and controls. , 2007, The Journal of allergy and clinical immunology.

[27]  K. Asadullah,et al.  Selective glucocorticoid receptor agonists (SEGRAs): Novel ligands with an improved therapeutic index , 2007, Molecular and Cellular Endocrinology.

[28]  Gonçalo R. Abecasis,et al.  Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma , 2007, Nature.

[29]  K. Schechtman,et al.  Epithelial cell proliferation contributes to airway remodeling in severe asthma. , 2007, American journal of respiratory and critical care medicine.

[30]  D. Elbirt,et al.  Patients and Methods , 2022 .

[31]  P. Chanez,et al.  Specificity of basement membrane thickening in severe asthma. , 2007, The Journal of allergy and clinical immunology.

[32]  H. Derendorf.  Pharmacokinetic and Pharmacodynamic Properties of Inhaled Ciclesonide , 2007, Journal of clinical pharmacology.

[33]  P. Barnes.  New molecular targets for the treatment of neutrophilic diseases. , 2007, The Journal of allergy and clinical immunology.

[34]  E. Israel,et al.  Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. , 2007, American journal of respiratory and critical care medicine.

[35]  I. Adcock,et al.  Therapeutic Potential of Phosphatidylinositol 3-Kinase Inhibitors in Inflammatory Respiratory Disease , 2007, Journal of Pharmacology and Experimental Therapeutics.

[36]  Trevor T. Hansel,et al.  Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases , 2007, Nature Reviews Drug Discovery.

[37]  Tomoki Ito,et al.  TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. , 2007, Annual review of immunology.

[38]  D. Curran‐Everett,et al.  IL4Rα Mutations Are Associated with Asthma Exacerbations and Mast Cell/IgE Expression , 2007 .

[39]  H. Hammad,et al.  Activation of the D prostanoid 1 receptor suppresses asthma by modulation of lung dendritic cell function and induction of regulatory T cells , 2007, The Journal of experimental medicine.

[40]  Ian M. Adcock,et al.  Regulation of Th2 Cytokine Genes by p38 MAPK-Mediated Phosphorylation of GATA-31 , 2007, The Journal of Immunology.

[41]  S. Pai,et al.  GATA-3 - not just for Th2 cells anymore. , 2007, Cellular & molecular immunology.

[42]  D. Curran‐Everett,et al.  Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. , 2007, The Journal of allergy and clinical immunology.

[43]  Jie Zhu,et al.  Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma , 2007, Thorax.

[44]  Irfan Rahman,et al.  Regulation of inflammation and redox signaling by dietary polyphenols. , 2006, Biochemical pharmacology.

[45]  P. Barnes.  New therapies for asthma. , 2006, Trends in molecular medicine.

[46]  M. Idzko,et al.  Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. , 2006, The Journal of clinical investigation.

[47]  D. Figarella-Branger,et al.  Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. , 2006, Genes & development.

[48]  S. Ward,et al.  Leukocyte navigation mechanisms as targets in airway diseases. , 2006, Drug discovery today.

[49]  K. Rabe,et al.  The effect of a single inhaled dose of a VLA‐4 antagonist on allergen‐induced airway responses and airway inflammation in patients with asthma , 2006, Allergy.

[50]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[51]  I. Rahman,et al.  Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. , 2006, Pharmacology & therapeutics.

[52]  J. Hammersley,et al.  Telithromycin in acute exacerbations of asthma. , 2006, The New England journal of medicine.

[53]  K. McIntyre,et al.  Selective Inhibition of Eosinophil Influx into the Lung by Small Molecule CC Chemokine Receptor 3 Antagonists in Mouse Models of Allergic Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[54]  R. Horne.  Compliance, adherence, and concordance: implications for asthma treatment. , 2006, Chest.

[55]  R. Coffman,et al.  Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. , 2006, American journal of respiratory and critical care medicine.

[56]  P. Barnes.  How corticosteroids control inflammation: Quintiles Prize Lecture 2005 , 2006, British journal of pharmacology.

[57]  A. Krieg,et al.  Therapeutic potential of Toll-like receptor 9 activation , 2006, Nature Reviews Drug Discovery.

[58]  S. Antoniu.  Targeting tumour necrosis factor-α in corticosteroid-dependent asthma , 2006 .

[59]  T. Chiba,et al.  Theophylline and Dexamethasone Induce Peroxisome Proliferator-Activated Receptor-γ Expression in Human Eosinophils , 2006, Pharmacology.

[60]  S. Johnston,et al.  The effect of telithromycin in acute exacerbations of asthma. , 2006, The New England journal of medicine.

[61]  M. Belvisi,et al.  Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. , 2006, European journal of pharmacology.

[62]  E. Hamelmann,et al.  Toll-like receptors--novel targets in allergic airway disease (probiotics, friends and relatives). , 2006, European journal of pharmacology.

[63]  S. Dahlén,et al.  Treatment of asthma with antileukotrienes: first line or last resort therapy? , 2006, European journal of pharmacology.

[64]  K. Chung,et al.  Phosphodiesterase inhibitors in airways disease , 2006 .

[65]  Kazuhiro Ito,et al.  Kinase inhibitors and airway inflammation. , 2006, European journal of pharmacology.

[66]  I. Adcock,et al.  Update on glucocorticoid action and resistance. , 2006, The Journal of allergy and clinical immunology.

[67]  L. Davis,et al.  Oxidative Stress Promotes Polarization of Human T Cell Differentiation Toward a T Helper 2 Phenotype1 , 2006, The Journal of Immunology.

[68]  N. Krug,et al.  Regulation of GATA-3, c-maf and T-bet mRNA Expression in Bronchoalveolar Lavage Cells and Bronchial Biopsies after Segmental Allergen Challenge , 2006, International Archives of Allergy and Immunology.

[69]  I. Pavord,et al.  Evidence of a role of tumor necrosis factor alpha in refractory asthma. , 2006, The New England journal of medicine.

[70]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[71]  M. Dallman,et al.  Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. , 2005, The Journal of clinical investigation.

[72]  Robert Newton,et al.  Ikappa-B kinase-2 inhibitor blocks inflammation in human airway smooth muscle and a rat model of asthma. , 2005, American journal of respiratory and critical care medicine.

[73]  J. Gulcher,et al.  Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[74]  S. Holgate,et al.  Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. , 2005, The Journal of allergy and clinical immunology.

[75]  M. Spellman,et al.  Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. , 2005, The Journal of allergy and clinical immunology.

[76]  Malcolm Johnson,et al.  Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. , 2005, American journal of respiratory and critical care medicine.

[77]  P. Howarth,et al.  Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. , 2005, Thorax.

[78]  A. Hoffmann,et al.  Molecular Determinants of Crosstalk between Nuclear Receptors and Toll-like Receptors , 2005, Cell.

[79]  P. Sterk,et al.  Effect of a very late antigen‐4 receptor antagonist on allergen‐induced airway responses and inflammation in asthma , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[80]  J. Bousquet,et al.  Comparison of roflumilast, an oral anti‐inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma , 2005, Allergy.

[81]  I. Adcock,et al.  Decreased histone deacetylase activity in chronic obstructive pulmonary disease. , 2005, The New England journal of medicine.

[82]  K. Rabe,et al.  Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. , 2005, The Journal of allergy and clinical immunology.

[83]  E. Meltzer,et al.  An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. , 2005, The Journal of allergy and clinical immunology.

[84]  I. Adcock,et al.  Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: effects of SP600125. , 2005, European journal of pharmacology.

[85]  E. Pizzichini,et al.  Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma , 2005, European Respiratory Journal.

[86]  W. Luttmann,et al.  Chemokine‐receptor expression on T cells in lung compartments of challenged asthmatic patients , 2005, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[87]  L. Ou,et al.  Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. , 2004, The Journal of allergy and clinical immunology.

[88]  R. Pauwels,et al.  Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. , 2004, American journal of respiratory and critical care medicine.

[89]  I. Adcock,et al.  Theophylline Restores Histone Deacetylase Activity and Steroid Responses in COPD Macrophages , 2004, The Journal of experimental medicine.

[90]  K. Broadley,et al.  Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. , 2004, Pulmonary pharmacology & therapeutics.

[91]  M. Hecker,et al.  Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. , 2004, The Journal of allergy and clinical immunology.

[92]  I. Adcock,et al.  Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. , 2004, American journal of respiratory and critical care medicine.

[93]  Kevin B Weiss,et al.  Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. , 2004, The Journal of allergy and clinical immunology.

[94]  D. Fabian,et al.  The global burden of asthma: executive summary of the GINA Dissemination Committee Report , 2004, Allergy.

[95]  V. Lagente,et al.  New nitric oxide-donating drugs for the treatment of airway diseases. , 2004, Current opinion in investigational drugs.

[96]  P. Finan,et al.  PI 3-kinase inhibition: a therapeutic target for respiratory disease. , 2004, Biochemical Society transactions.

[97]  P. Rothman,et al.  Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells , 2004 .

[98]  I. Adcock,et al.  Allergen‐induced inflammation and airway epithelial and smooth muscle cell proliferation: role of Jun N‐terminal kinase , 2003, British journal of pharmacology.

[99]  Isabelle Vachier,et al.  Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. , 2003, American journal of respiratory and critical care medicine.

[100]  P. Shah,et al.  Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD , 2003, Thorax.

[101]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[102]  I. Adcock,et al.  Glucocorticoid Receptor Nitration Leads to Enhanced Anti-Inflammatory Effects of Novel Steroid Ligands 1 , 2003, The Journal of Immunology.

[103]  I. Adcock,et al.  Corticosteroid-insensitive asthma: molecular mechanisms. , 2003, The Journal of endocrinology.

[104]  K. Nakashima,et al.  The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in Rodents , 2003, Journal of Pharmacology and Experimental Therapeutics.

[105]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[106]  D. Postma,et al.  Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. , 2003, American journal of respiratory and critical care medicine.

[107]  Khusru Asadullah,et al.  Mechanisms involved in the side effects of glucocorticoids. , 2002, Pharmacology & therapeutics.

[108]  I. Adcock,et al.  Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma. , 2002, Clinical immunology.

[109]  C. Page,et al.  Novel drug development opportunities for heparin , 2002, Nature Reviews Drug Discovery.

[110]  P. Herrlich,et al.  Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor , 2001, The EMBO journal.

[111]  I. Adcock,et al.  Expression of GATA family of transcription factors in T-cells, monocytes and bronchial biopsies. , 2001, The European respiratory journal.

[112]  W. Busse,et al.  Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. , 2001, The Journal of allergy and clinical immunology.

[113]  L. Fabbri,et al.  The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. , 2001, The Journal of clinical investigation.

[114]  S. Suissa,et al.  Inhaled corticosteroids: impact on asthma morbidity and mortality. , 2001, The Journal of allergy and clinical immunology.

[115]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[116]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[117]  Stephen T Holgate,et al.  Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response , 2000, The Lancet.

[118]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[119]  A. Sousa,et al.  In vivo resistance to corticosteroids in bronchial asthma is associated with enhanced phosyphorylation of JUN N-terminal kinase and failure of prednisolone to inhibit JUN N-terminal kinase phosphorylation. , 1999, The Journal of allergy and clinical immunology.

[120]  M. Gaestel,et al.  MAPKAP kinase 2 is essential for LPS-induced TNF-α biosynthesis , 1999, Nature Cell Biology.

[121]  D. Postma,et al.  Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. , 1999, The European respiratory journal.

[122]  D. H. Zhang,et al.  Gene expression of the GATA-3 transcription factor is increased in atopic asthma. , 1999, The Journal of allergy and clinical immunology.

[123]  I. Adcock,et al.  Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. , 1998, American journal of respiratory and critical care medicine.

[124]  P. Barnes,et al.  Haplotype associated with low interleukin-10 production in patients with severe asthma , 1998, The Lancet.

[125]  C. Mackay,et al.  Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co‐localization of eotaxin mRNA to bronchial epithelial and endothelial cells , 1997, European journal of immunology.

[126]  M. Turner,et al.  Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells. , 1996, Oncogene.

[127]  P. Barnes,et al.  Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. , 1996, Thorax.

[128]  P. Barnes,et al.  The costs of asthma. , 1996, The European respiratory journal.

[129]  G. Mills,et al.  Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils , 1996, The Journal of experimental medicine.

[130]  P. Barnes,et al.  Inhaled glucocorticoids for asthma. , 1995, The New England journal of medicine.

[131]  D. Solit,et al.  Development and application of Hsp90 inhibitors. , 2008, Drug discovery today.

[132]  Mario Castro,et al.  Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. , 2008, The Journal of allergy and clinical immunology.

[133]  M. Cazzola,et al.  ultra-long-acting beta2-adrenoceptor agonists: an emerging therapeutic option for asthma and COPD? , 2007, Drugs.

[134]  Chih-Hung Hsu,et al.  Clinical studies with curcumin. , 2007, Advances in experimental medicine and biology.

[135]  F. Kalkbrenner,et al.  Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. , 2007, American journal of respiratory cell and molecular biology.

[136]  Malcolm W Johnson.  Molecular mechanisms of β2-adrenergic receptor function, response, and regulation , 2006 .

[137]  P. Barnes,et al.  Effects of corticosteroids on noninvasive biomarkers of inflammation in asthma and chronic obstructive pulmonary disease. , 2004, Proceedings of the American Thoracic Society.

[138]  I. Adcock,et al.  Combination Therapy of Long-Acting β2-Adrenoceptor Agonists and Corticosteroids for Asthma , 2004, Treatments in respiratory medicine.

[139]  C. Akdis,et al.  Mechanisms of allergen-specific immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[140]  M. Gaestel,et al.  Kotlyarov, A. et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat. Cell Biol. 1, 94-97 , 1999 .

[141]  I. Adcock,et al.  Journal of Occupational Medicine and Toxicology New Drugs Targeting Th2 Lymphocytes in Asthma , 2022 .